托珠单抗联合糖皮质激素治疗住院COVID-19患者的死亡率:对既往荟萃分析的贝叶斯再分析
该研究是对WHO一项托珠单抗荟萃分析的贝叶斯分层再分析,纳入15项随机临床试验中仅接受糖皮质激素的5339例住院COVID-19患者。主要终点为随机化后28天全因死亡率。在弱信息先验下,仅简单氧疗者生存OR为0.70(95%CrI 0.50-0.91),NIV者为0.81(95%CrI 0.63-1.03),IMV者为0.89(95%CrI 0.61-1.22)。仅简单氧疗和NIV亚组有临床意义关联的后验概率分别大于95%和大于90%,而IMV亚组仅约67%。结论认为未来研究应明确IMV患者是否也从托珠单抗获益。
要点
- 在仅接受糖皮质激素的住院COVID-19患者中,仅简单氧疗者使用托珠单抗的28天生存OR为0.70(95%CrI 0.50-0.91),后验概率98.9%提示任何获益。
- NIV亚组生存OR为0.81(95%CrI 0.63-1.03),任何获益后验概率95.5%,临床意义关联(绝对死亡风险差>1%)后验概率大于90%。
- IMV亚组生存OR为0.89(95%CrI 0.61-1.22),任何获益后验概率75.4%,临床意义关联后验概率仅约67%。
- 仅简单氧疗亚组托珠单抗优于NIV和IMV亚组的概率分别为85%和90%;预测区间显示仅72.1%的未来IMV研究将显示获益。
- 结论不随先验分布改变而改变,未来研究应明确IMV患者是否也从托珠单抗获益。
适用人群与场景
- 住院COVID-19患者,来自15项随机临床试验,仅纳入接受糖皮质激素的患者;共5339例,多数为男性,平均年龄56至66岁。
- 按呼吸支持方式分为:仅简单氧疗2117例,无创通气(NIV)2505例,有创机械通气(IMV)717例。
处置流程与药物剂量
- 干预为常规治疗加托珠单抗,对照为常规治疗或安慰剂;原文未给出托珠单抗的具体剂量、给药途径和疗程。
研究设计与关键结果
- 研究类型:对WHO托珠单抗荟萃分析(2020年和2021年发表)的贝叶斯分层再分析,采用弱信息先验,并用模糊先验和信息先验评估稳健性。
- 主要终点为随机化后28天全因死亡率;在弱信息先验下,仅简单氧疗者生存OR 0.70(95%CrI 0.50-0.91),NIV者OR 0.81(95%CrI 0.63-1.03),IMV者OR 0.89(95%CrI 0.61-1.22)。
- 任何获益(OR<1)的后验概率:仅简单氧疗98.9%,NIV 95.5%,IMV 75.4%。
- 临床意义关联(绝对死亡风险差>1%)的后验概率:仅简单氧疗大于95%,NIV大于90%,IMV约67%。
- 仅简单氧疗亚组托珠单抗优于NIV和IMV亚组的概率分别为85%和90%;预测区间显示仅72.1%的未来IMV研究将显示获益。
- 结论不随不同先验分布改变。
证据类型、等级与局限
- 证据类型:对15项随机临床试验的贝叶斯再分析;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于仅接受简单氧疗或NIV的住院COVID-19患者,使用托珠单抗联合糖皮质激素与临床意义的死亡获益相关。
- 作者指出,未来研究应明确IMV患者是否也从托珠单抗获益。
指南或共识出处
- 世界卫生组织(WHO)托珠单抗荟萃分析(2020年和2021年发表的研究)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: A World Health Organization (WHO) meta-analysis found that tocilizumab was associated with reduced mortality in hospitalized patients with COVID-19. However, uncertainty remains concerning the magnitude of tocilizumab's benefits and whether its association with mortality benefit is similar across respiratory subgroups.
OBJECTIVE: To use bayesian methods to assess the magnitude of mortality benefit associated with tocilizumab and the differences between respiratory support subgroups in hospitalized patients with COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: A bayesian hierarchical reanalysis of the WHO meta-analysis of tocilizumab studies published in 2020 and 2021 was performed. Main results were estimated using weakly informative priors to exert little influence on the observed data. The robustness of these results was evaluated using vague and informative priors. The studies featured in the meta-analysis were randomized clinical tocilizumab trials of hospitalized patients with COVID-19. Only patients receiving corticosteroids were included.
INTERVENTIONS: Usual care plus tocilizumab in comparison with usual care or placebo.
MAIN OUTCOMES AND MEASURES: All-cause mortality at 28 days after randomization.
RESULTS: Among the 5339 patients included in this analysis, most were men, with mean ages between 56 and 66 years. There were 2117 patients receiving simple oxygen only, 2505 receiving noninvasive ventilation (NIV), and 717 receiving invasive mechanical ventilation (IMV) in 15 studies from multiple countries and continents. Assuming weakly informative priors, the overall odds ratios (ORs) for survival were 0.70 (95% credible interval [CrI], 0.50-0.91) for patients receiving simple oxygen only, 0.81 (95% CrI, 0.63-1.03) for patients receiving NIV, and 0.89 (95% CrI, 0.61-1.22) for patients receiving IMV, respectively. The posterior probabilities of any benefit (OR <1) were notably different between patients receiving simple oxygen only (98.9%), NIV (95.5%), and IMV (75.4%). The posterior probabilities of a clinically meaningful association (absolute mortality risk difference >1%) were greater than 95% in patients receiving simple oxygen only and greater than 90% in patients receiving NIV. In contrast, the posterior probability of this clinically meaningful association was only approximately 67% in patients receiving IMV. The probabilities of tocilizumab superiority in the simple oxygen only subgroup compared with the NIV and IMV subgroups were 85% and 90%, respectively. Predictive intervals highlighted that only 72.1% of future tocilizumab IMV studies would show benefit. The conclusions did not change with different prior distributions.
CONCLUSIONS AND RELEVANCE: In this bayesian reanalysis of a previous meta-analysis of 15 studies of hospitalized patients with COVID-19 treated with tocilizumab and corticosteroids, use of simple oxygen only and NIV was associated with a probability of a clinically meaningful mortality benefit from tocilizumab. Future research should clarify whether patients receiving IMV also benefit from tocilizumab.
参考来源
- Albuquerque AM, Tramujas L, Sewanan LR, et al. Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids: A Bayesian Reanalysis of a Previous Meta-analysis. JAMA Netw Open. 2022. PMID: 35226077. doi:10.1001/jamanetworkopen.2022.0548
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。